GID BIO IN THE NEWS
Read how recent cell-based therapy discoveries are impacting the field of medicine.
Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements”
As the total number of confirmed COVID-19 cases surpasses five million in the US, companies across the country are researching potential diagnostic tests, vaccines and treatment options. With recent clearance from the FDA, our team joins the force of a limited number of cell and gene therapies being studied in
Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study cellular therapy as a potential therapeutic for severe respiratory distress
Study to treat hospitalized COVID-19 patients applies same technology platform and point-of-care cellular therapy used in a pivotal/Phase III trial for osteoarthritis LOUISVILLE, Colo. and PITTSBURGH, Aug. 18, 2020 /PRNewswire/ — Following FDA clearance of an expanded access protocol to treat a small group of COVID-19 patients using the GID BIO technology platform,
Bostock joins late-stage biotech as pivotal Phase III trial gets underway for cellular therapy for osteoarthritis of the knee LOUISVILLE, Colo., July 28, 2020 /PRNewswire/ — Roy J. Bostock, former Chairman of Yahoo!, Vice Chairman of Delta Airlines and a director of Morgan Stanley, has joined the cellular medicine startup
Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting firms, corporates and other M&A professionals around the world. WWW.MERGERMARKET.COM JANUARY 16, 2020 BY DEB BALSHEM GID BIO, a privately held cellular therapy company, is looking to raise between USD
An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France
GID BIO CEO William Cimino, PhD sat down with SmartTRAK, BioMedGPS Senior Analyst, Regenerative Medicine at the International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France. Click here to listen to the full interview.
Multiple orthobiologic companies have engaged in clinical trials in 2019, seeking to demonstrate the efficacy of their cell-based products…. GID BIO completed a multi-site, randomized, placebo-controlled Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…